CME Breakfast Symposium
7:00 AM – 11:00 AM

Hyatt Regency Orlando
Plaza International Ballroom G & H
9801 International Drive
Orlando, FL

7:00 AM Registration and Breakfast
7:40 AM Welcome
  Lee Greenberger, PhD
Chief Scientific Officer, LLS
7:45 AM Introduction
  Larry W. Kwak, MD, PhD
7:50 AM Molecularly Targeted Therapy of Acute Myeloid Leukemia (AML)
  A. Thomas Look, MD
8:20 AM Dissecting and Targeting Resistance in ALL
  Adolfo Ferrando, MD, PhD
8:50 AM Advances in Biology and Treatments of Patients with Chronic Lymphocytic Leukemia
  Thomas J. Kipps, MD, PhD
9:20 AM Aberrant Metabolism in Hematopoietic Malignancies and Its Therapeutic Implications
  Pier Paolo Pandolfi, MD, PhD
9:50 AM Insights into the Pathophysiology and Therapeutic Targeting of Treatment Resistance in Myeloma
  Constantine S. Mitsiades, MD, PhD
10:20 AM Panel Discussion and Q&A

Larry W. Kwak, MD, PhD, A. Thomas Look, MD, Adolfo Ferrando, MD, PhD, Thomas J. Kipps, MD, PhD, Pier Paolo Pandolfi, MD, PhD, Constantine S. Mitsiades, MD, PhD

11:00 AM Adjourn



Larry W. Kwak, MD, PhD
Director, Toni Stephenson Lymphoma Center
Dr. Michael Friedman Professor for Translational Medicine
Cancer Center Associate Director, Translational Research and Developmental Therapeutics
City of Hope National Medical Center
Duarte, CA

A. Thomas Look, MD
Vice Chair for Research, Department of Pediatric Oncology, Dana-Farber Cancer Institute
Professor of Pediatrics, Harvard Medical School
Boston, MA

Adolfo Ferrando, MD, PhD
Associate Professor of Pediatrics and Pathology
Associate Director for Research, Pediatric Oncology Division
Columbia University
New York, NY

Thomas J. Kipps, MD, PhD
Evelyn and Edwin Tasch Chair in Cancer Research
Distinguished Professor of Medicine
Deputy Director,
Research Operations
UCSD, Moores Cancer Center, La Jolla
San Diego, CA

Pier Paolo Pandolfi, MD, PhD
George C. Reisman Professor of Medicine
Professor of Pathology,
Harvard Medical School
Cancer Center at Beth Israel Deaconess Medical Center (BIDMC) and the Cancer Research Institute at BIDMC
Chief, Division of Genetics, Department of Medicine, BIDMC
Boston, MA

Constantine S. Mitsiades, MD, PhD
Assistant Professor of Medicine
Department of Medical Oncology, Dana-Farber Cancer Institute
Department of Medicine, Harvard Medical School
Boston, MA

This activity is primarily for researchers in hematology/oncology and for hematologists and oncologists who diagnose and treat patients with hematologic malignancies. The program is designed to provide the intended audience with cutting-edge research about newly approved and emerging molecularly targeted therapeutics in treating and improving outcomes of patients with hematologic malignancies.

It is evident that we have entered an era of targeted therapy with the completion of human genome sequencing and approval of multiple drugs against specific molecular targets in both solid tumors and hematologic malignancies. Despite challenges in tumor heterogeneity due in part to mutations, dysregulated gene and epigenetic regulation at both DNA and RNA levels, and altered signaling pathways, advances in the field of molecular therapy are rather rapid and promising for hematologic malignancies. Therefore, in order for researchers and clinicians to have the greatest impact on cancer treatment now and in the future, it is vital that they comprehend the development of molecularly targeted therapies at the levels of cutting-edge technologies, dysregulated pathways and molecular targets, mechanisms of action underlying specific drugs, and selection of subset patients based on molecular signatures to receive the most benefits.1-5


1. Zhang S, Kipps T J. The pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol. 2014;9:103-118.
2. Mansour MR, Abraham BJ, Anders L, et al. Oncogene regulation: an oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science. 2014;346(6215):1373–1377.
3. Tzoneva G, Perez-Garcia A, Carpenter Z, et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med. 2013;19(3):368-371.
4. Kats LM, Reschke M, Taulli R, et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell. 2014;14(3):329341.
5. Ocio EM, Mitsiades CS, Orlowski RZ, Anderson KC. Future agents and treatment directions in multiple myeloma. Expert Rev Hematol. 2014;7(1):127141.

After completing this activity, participants should be better able to:

  • Use advances in molecularly targeted therapies in multiple hematologic malignancies, such as ALL, AML, CLL, and multiple myeloma
  • Describe currently approved molecularly targeted therapies for above-mentioned hematologic malignancies and potential emerging therapies
  • Explain the mechanisms of action of various therapies, including their roles in hematologic malignancies
  • Describe key factors related to the use of molecularly targeted therapies for hematologic malignancies
  • Engage patients and caregivers in clinical trials discussions about emerging molecularly targeted therapies
  • Describe how to optimize the use of emerging molecularly targeted therapies with chemotherapies or immunotherapies to maximally benefit patients


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Leukemia & Lymphoma Society, RMEI, LLC, and Postgraduate Institute for Medicine. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Postgraduate Institute for Medicine designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

There is no fee for this educational activity.

Event staff will be glad to assist you with any special needs (physical, dietary, etc.). Please contact us prior to the live event at (866) 992-9950.

This activity is jointly provided by The Leukemia & Lymphoma Society, RMEI, LLC, and Postgraduate Institute for Medicine. Funding provided by The Leukemia & Lymphoma Society.

For information on leukemia, lymphoma, or myeloma, contact an LLS Information Specialist at (800) 955-4572 or or visit


Facebook Twitter YouTube